News
Video
Author(s):
IMROZ (NCT03319667) is the first global Phase 3 study of an anti-CD38 mAb in combination with VRd in patients with transplant-ineligible NDMM.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Tambiciclib Plus Zanubrutinib Delivers Responses in R/R DLBCL
FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL
Ide-Cel Boosts Response in Myeloma With < CR After Upfront Auto-HCT and Lenalidomide Maintenance
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
FOXP3/Helios Expression in CD4+ Tcons Correlates With T-Cell Activation After Orca-T in Hematologic Malignancies
Five Under 5: Top Oncology Videos for the Week of 2/9
FDA Grants Fast Track Status to SIGX1094 for Diffuse Gastric Cancer
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Epcoritamab Elicits Durable CR Rates, Increases MRD Negativity in Relapsed/Refractory DLBCL
Learning to Dance
UT MD Anderson and Texas Children’s Hospital Announce Joint Venture to End Childhood Cancer